AU2812589A - Factors associated with essential hypertension - Google Patents

Factors associated with essential hypertension

Info

Publication number
AU2812589A
AU2812589A AU28125/89A AU2812589A AU2812589A AU 2812589 A AU2812589 A AU 2812589A AU 28125/89 A AU28125/89 A AU 28125/89A AU 2812589 A AU2812589 A AU 2812589A AU 2812589 A AU2812589 A AU 2812589A
Authority
AU
Australia
Prior art keywords
factors associated
essential hypertension
hypertension
essential
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28125/89A
Inventor
Suhail Ahmad
Amitava Dasgupta
Margaret A. Kenny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of AU2812589A publication Critical patent/AU2812589A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
AU28125/89A 1987-10-29 1988-10-28 Factors associated with essential hypertension Abandoned AU2812589A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11593487A 1987-10-29 1987-10-29
US115934 1987-10-29
US19462988A 1988-05-16 1988-05-16
US194629 2002-07-12

Publications (1)

Publication Number Publication Date
AU2812589A true AU2812589A (en) 1989-05-23

Family

ID=26813726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28125/89A Abandoned AU2812589A (en) 1987-10-29 1988-10-28 Factors associated with essential hypertension

Country Status (5)

Country Link
EP (1) EP0386140A1 (en)
JP (1) JPH03501850A (en)
AU (1) AU2812589A (en)
IL (1) IL88262A0 (en)
WO (1) WO1989003836A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
AU643685B2 (en) * 1989-03-22 1993-11-25 Peter K.T. Pang Parathyroid hypertensive factor
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
WO1993025577A2 (en) * 1992-06-12 1993-12-23 Zenyaku Kogyo Co., Ltd. Active component of parathyroid hypertensive factor
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577446A (en) * 1968-09-09 1971-05-04 American Home Prod Phosphatidylalkanolamine derivatives
US4321120A (en) * 1980-03-19 1982-03-23 Nardi Ronald V Process for detecting proteins specific to hypertension in mammals
AU559292B2 (en) * 1984-12-28 1987-03-05 Terumo Kabushiki Kaisha Polymerisable liposome-forming lipids

Also Published As

Publication number Publication date
WO1989003836A1 (en) 1989-05-05
JPH03501850A (en) 1991-04-25
EP0386140A1 (en) 1990-09-12
IL88262A0 (en) 1989-06-30

Similar Documents

Publication Publication Date Title
AU614965B2 (en) Thiadiazinones
AU3151689A (en) Improved cryo-slammer
AU2378688A (en) Improved membrane-supported immunoassays
AU2611588A (en) New phenylethanolamines
AU1407388A (en) Substituted di-t-butylphenols
AU2222388A (en) Peptidylheterocycles
AU1842588A (en) Luminaires
AU1381888A (en) Timeswitches
AU1301788A (en) Chemo-radio-immuno-conjugates
AU2142288A (en) New aluminium-magnesium-hydroxy-compounds
AU1764488A (en) Substituted 5-methylamino-1-arylpyrazoles
AU2370188A (en) Supercharger
AU1210388A (en) Novel aminohydrocarbyl-substituted ketoximosilanes
AU2665388A (en) 17-methylene-and 17-ethylidene-estratrienes
AU618619B2 (en) Novel combination
AU1590788A (en) Leukaemia-inhibitory factor
AU1158888A (en) Scraper-spreader
AU1366388A (en) Videosystem
AU2812589A (en) Factors associated with essential hypertension
AU2038288A (en) Styrenic-polyamide-elastomer blends
AU2480888A (en) Improved liner configuration
AU2456688A (en) Dripulator
AU2021888A (en) Sulphonylaminoguanidinoazines
AU2698888A (en) Naphthothiazepinones
AU2505988A (en) 3-aminopyrazolin-5-ones